T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus

Cellular Immunology

Volumn 271, Issue 1, 2011, Pages 110-117

  Loza, Matthew J ^a   Shane Anderson, A ^a   O'Rourke, Kenneth S ^a   Wood, James ^a   Khan, Islam U ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Autoimmunity; Human lupus; NTPDase CD39; Regulatory T cells

Indexed keywords

ADENOSINE; AZATHIOPRINE; BIOLOGICAL MARKER; CD39 ANTIGEN; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMIDINE DERIVATIVE; THYMIDINE H 3; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD25+ T LYMPHOCYTE; CELL CULTURE; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MEDIATOR; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADENOSINE; ADULT; AGED; ANTIGENS, CD; APYRASE; BIOLOGICAL MARKERS; CELL PROLIFERATION; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; XANTHINES;

EID: 80052365787     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.06.010     Document Type: Article

References (36)

1. Karim M., Feng G., Wood K.J., Bushell A.R. CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005, 105:4871-4877.
2. Thornton A.M., Shevach E.M. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 2000, 164:183-190.
3. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., Gottlieb P.A., Kapranov P., Gingeras T.R., Fazekas de St Groth B., Clayberger C., Soper D.M., Ziegler S.F., Bluestone J.A. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006, 203:1701-1711.
4. Chen C., Rowell E.A., Thomas R.M., Hancock W.W., Wells A.D. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J. Biol. Chem. 2006, 281:36828-36834.
5. Gavin M.A., Torgerson T.R., Houston E., DeRoos P., Ho W.Y., Stray-Pedersen A., Ocheltree E.L., Greenberg P.D., Ochs H.D., Rudensky A.Y. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. USA 2006, 103:6659-6664.
6. Torgerson T.R. Regulatory T cells in human autoimmune diseases. Springer Semin. Immunopathol. 2006, 28:63-76.
7. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur. J. Immunol. 2007, 37:129-138.
8. Miyara M., Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 2007, 13:108-116.
9. Borsellino G., Kleinewietfeld M., Di Mitri D., Sternjak A., Diamantini A., Giometto R., Hopner S., Centonze D., Bernardi G., Dell'Acqua M.L., Rossini P.M., Battistini L., Rotzschke O., Falk K. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
10. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., Chen J.F., Enjyoji K., Linden J., Oukka M., Kuchroo V.K., Strom T.B., Robson S.C. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204:1257-1265.
11. Kobie J.J., Shah P.R., Yang L., Rebhahn J.A., Fowell D.J., Mosmann T.R. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J. Immunol. 2006, 177:6780-6786.
12. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001, 414:916-920.
13. Sitkovsky M.V., Ohta A. The 'danger' sensors that STOP the immune response: the A2 adenosine receptors?. Trends Immunol. 2005, 26:299-304.
14. Huang S., Apasov S., Koshiba M., Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997, 90:1600-1610.
15. Mandapathil M., Hilldorfer B., Szczepanski M.J., Czystowska M., Szajnik M., Ren J., Lang S., Jackson E.K., Gorelik E., Whiteside T.L. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem. 2010, 285:7176-7186.
16. Lee J.H., Wang L.C., Lin Y.T., Yang Y.H., Lin D.T., Chiang B.L. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 2006, 117:280-286.
17. Mellor-Pita S., Citores M.J., Castejon R., Tutor-Ureta P., Yebra-Bango M., Andreu J.L., Vargas J.A. Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2006, 65:553-554.
18. Miyara M., Amoura Z., Parizot C., Badoual C., Dorgham K., Trad S., Nochy D., Debre P., Piette J.C., Gorochov G. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J. Immunol. 2005, 175:8392-8400.
19. Suarez A., Lopez P., Gomez J., Gutierrez C. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann. Rheum. Dis. 2006, 65:1512-1517.
20. Bonelli M., Savitskaya A., Steiner C.W., Rath E., Smolen J.S., Scheinecker C. Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J. Immunol. 2009, 182:1689-1695.
21. Alvarado-Sanchez B., Hernandez-Castro B., Portales-Perez D., Baranda L., Layseca-Espinosa E., Abud-Mendoza C., Cubillas-Tejeda A.C., Gonzalez-Amaro R. Regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 2006, 27:110-118.
22. Valencia X., Yarboro C., Illei G., Lipsky P.E. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 2007, 178:2579-2588.
23. Kammer G.M. High prevalence of T cell type I protein kinase A deficiency in systemic lupus erythematosus. Arthritis Rheum. 1999, 42:1458-1465.
24. Laxminarayana D., Khan I.U., Mishra N., Olorenshaw I., Tasken K., Kammer G.M. Diminished levels of protein kinase A RI alpha and RI beta transcripts and proteins in systemic lupus erythematosus T lymphocytes. J. Immunol. 1999, 162:5639-5648.
25. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40:1725.
26. Miltenyi S., Muller W., Weichel W., Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 1990, 11:231-238.
27. Antonysamy M.A., Moticka E.J., Ramkumar V. Adenosine acts as an endogenous modulator of IL-2-dependent proliferation of cytotoxic T lymphocytes. J. Immunol. 1995, 155:2813-2821.
28. Jacobson K.A., Ukena D., Kirk K.L., Daly J.W. [3H]xanthine amine congener of 1, 3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. Proc. Natl. Acad. Sci. USA 1986, 83:4089-4093.
29. Bermas B.L., Petri M., Goldman D., Mittleman B., Miller M.W., Stocks N.I., Via C.S., Shearer G.M. T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity. J. Clin. Immunol. 1994, 14:169-177.
30. Crow M.K. Enhancement of the impaired autologous mixed leukocyte reaction in patients with systemic lupus erythematosus. J. Clin. Invest. 1985, 76:807-815.
31. Khan I.U., Laxminarayana D., Kammer G.M. Protein kinase A RI beta subunit deficiency in lupus T lymphocytes: bypassing a block in RI beta translation reconstitutes protein kinase A activity and augments IL-2 production. J. Immunol. 2001, 166:7600-7605.
32. Tsokos G.C., Kammer G.M. Molecular aberrations in human systemic lupus erythematosus. Mol. Med. Today 2000, 6:418-424.
33. Via C.S., Tsokos G.C., Bermas B., Clerici M., Shearer G.M. T cell-antigen-presenting cell interactions in human systemic lupus erythematosus. Evidence for heterogeneous expression of multiple defects. J. Immunol. 1993, 151:3914-3922.
34. Venigalla R.K., Tretter T., Krienke S., Max R., Eckstein V., Blank N., Fiehn C., Ho A.D., Lorenz H.M. Reduced CD4+, CD25- T cell sensitivity to the suppressive function of CD4+, CD25high, CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 2008, 58:2120-2130.
35. Feng L., Sun X., Csizmadia E., Han L., Bian S., Murakami T., Wang X., Robson S.C., Wu Y. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia 2011, 13:206-216.
36. Mandapathil M., Szczepanski M.J., Szajnik M., Ren J., Lenzner D.E., Jackson E.K., Gorelik E., Lang S., Johnson J.T., Whiteside T.L. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin. Cancer Res. 2009, 15:6348-6357.